SOFTMEDX (00648) announced its final results for the period ending 2025. The group recorded revenue of HK$68.243 million, representing an increase of 24.9% compared to the previous year. However, the annual profit was HK$6.95 million, a sharp decrease of 97.87% year-on-year. The basic earnings per share stood at HK$0.012.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.